Skip to main content
main-content

01.12.2014 | Research | Ausgabe 1/2014 Open Access

Journal of Ovarian Research 1/2014

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer

Zeitschrift:
Journal of Ovarian Research > Ausgabe 1/2014
Autoren:
Anita Monika Chudecka-Głaz, Aneta Alicja Cymbaluk-Płoska, Janusz Leszek Menkiszak, Agnieszka Monika Sompolska-Rzechuła, Aleksandra Izabela Tołoczko-Grabarek, Izabella Anna Rzepka-Górska
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1757-2215-7-62) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ACG have made substantial contributions to conception and design, planned and ran the experiments, collected data, performed analysis and interpretation of the results, review the literature and wrote the manuscript. ACP have contributed in collected data. JM have contributed in literature review. ASR supervised statistical analysis. ATG worked as pathologist. IRG have given final approval of the version to be published. All authors read and approved the final manuscript.

Abstract

Background

The most important prognostic factor in the ovarian cancer is optimal cytoreduction. The neoadjuvant chemotherapy, an only optional method of treatment in this case and is still the subject of debate. The object of this study was to evaluate the usefulness of markers: CA 125, HE4, YKL-40 and bcl-2 as well as cathepsin L in predicting optimal cytoreduction and response to chemotherapy.

Methods

Sera were secured preoperatively. The division into groups was performed retrospectively depending on the method of treatment (surgery vs neoadjuvant chemotherapy) as well as on response to chemotherapy (sensitive vs resistant vs refractory). Comparisons were made between groups, and the diagnostic usefulness of tested proteins was examined.

Results

We found that statistically significant differences between primary operated patients and patients undergoing neoadjuvant chemotherapy were applicable only to the tumour markers (CA125 1206.79 vs 2432.38, p = 0.000191; HE4 78.87 vs 602.45, p = 0.000004; YKL-40 108.13 vs 203.96, p = 0.003991). Cathepsin-L and Bcl-2 were statistically insignificant. The cut-off point values were determined for the CA 125 (345 mIU/ml), HE4 (218.43 pmol/L) and YKL-40 (140.9 ng/ml). The sensitivity, specificity, PPV and NPV were as follows: CA125 (83.3%; 75%; 80.6%; 78.3%), HE4 (86.6%; 91.3%; 92.9%; 84%) and YKL-40 (75%; 83.3%; 84%; 74.1%).

Conclusion

Among the tested proteins the HE4 marker appears to be helpful in forecasting of optimal cytoreduction and possibly also of the prediction of response to platinum analogues used in first-line treatment of ovarian cancer.
Zusatzmaterial
Authors’ original file for figure 1
13048_2014_280_MOESM1_ESM.tiff
Authors’ original file for figure 2
13048_2014_280_MOESM2_ESM.tiff
Authors’ original file for figure 3
13048_2014_280_MOESM3_ESM.tiff
Authors’ original file for figure 4
13048_2014_280_MOESM4_ESM.pdf
Authors’ original file for figure 5
13048_2014_280_MOESM5_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2014

Journal of Ovarian Research 1/2014 Zur Ausgabe


 

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Meistgelesene Bücher aus dem Fachgebiet

2014 | Buch

Perikonzeptionelle Frauenheilkunde

Fertilitätserhalt, Prävention und Management von Schwangerschaftsrisiken

Ein Praxisbuch für alle, die in der Beratung und Betreuung von Schwangeren und Paaren mit Kinderwunsch tätig sind. Die Herausgeber und Autoren haben alle wichtigen Informationen zusammengetragen, um Frauen sicher zu beraten, zu betreuen und kompetent Verantwortung zu übernehmen.

Herausgeber:
Christian Gnoth, Peter Mallmann

2019 | Buch

Praxisbuch Gynäkologische Onkologie

Dieses kompakte und praxisrelevante Standardwerk richtet sich alle Ärzte in Klinik und Praxis, die Patientinnen mit bösartigen Tumoren des Genitales und der Mamma behandeln. Die 5. Auflage wurde komplett aktualisiert und auf der Basis …

Herausgeber:
Prof. Dr. Edgar Petru, Dr. Daniel Fink, Prof. Dr. Ossi R. Köchli, Prof. Dr. Sibylle Loibl

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Gynäkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise